Circ Heart Fail
Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (N.K., A.P.).
Published: February 2024
Background: Utilization patterns of bariatric surgery among older patients with heart failure (HF), and the associations with cardiovascular outcomes, are not well known.
Methods: Medicare beneficiaries with HF and at least class II obesity from 2013 to 2020 were identified with Medicare Provider Analysis and Review 100% inpatient files and Medicare 5% outpatient files. Patients who underwent bariatric surgery were matched to controls in a 1:2 ratio (matched on exact age, sex, race, body mass index, HF encounter year, and HF hospitalization rate pre-surgery/matched period). In an exploratory analysis, patients prescribed pharmacotherapies with weight loss effects (semaglutide, liraglutide, naltrexone-bupropion, or orlistat) were identified and matched to controls with a similar strategy in addition to HF medical therapy data. Cox models evaluated associations between weight loss therapies (as a time-varying covariate) and mortality risk and HF hospitalization rate (calculated as the rate of HF hospitalizations following index HF encounter per 100 person-months) during follow-up.
Results: Of 298 101 patients with HF and body mass index ≥35 kg/m, 2594 (0.9%) underwent bariatric surgery (45% men; mean age, 56.2 years; mean body mass index, 51.5 kg/m). In propensity-matched analyses over a median follow-up of 4.7 years, bariatric surgery was associated with lower risk of all-cause mortality (HR, 0.55 [95% CI, 0.49-0.63]; <0.001), greater reduction in HF hospitalization rate (rate ratio, 0.72 [95% CI, 0.67-0.77]; <0.001), and lower atrial fibrillation risk (HR, 0.78 [95% CI, 0.65-0.93]; =0.006). Use of pharmacotherapies with weight loss effects was low (4.8%), with 96.3% prescribed GLP-1 (glucagon-like peptide-1) agonists (semaglutide, 23.6%; liraglutide, 72.7%). In propensity-matched analysis over a median follow-up of 2.8 years, patients receiving pharmacotherapies with weight loss effects (versus matched controls) had a lower risk of all-cause mortality (HR, 0.82 [95% CI, 0.71-0.95]; =0.007) and HF hospitalization rate (rate ratio, 0.87 [95% CI, 0.77-0.99]; =0.04).
Conclusions: Bariatric surgery and pharmacotherapies with weight loss effects are associated with a lower risk of adverse outcomes among older patients with HF and obesity; however, overall utilization remains low.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.122.010453 | DOI Listing |
J Med Case Rep
January 2025
Department of Surgery, Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, USA.
Background: Classic congenital adrenal hyperplasia, primarily due to 21-hydroxylase deficiency, leads to impaired cortisol and aldosterone production and excess adrenal androgens. Lifelong glucocorticoid therapy is required, often necessitating supraphysiological doses in youth to manage androgen excess and growth acceleration. These patients experience higher obesity rates, hypertension, and glucose metabolism issues, complicating long-term health management.
View Article and Find Full Text PDFBMC Surg
January 2025
Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Background: Metabolic and bariatric surgery (MBS) is a suitable solution for the treatment of morbid obesity. Investigating an MBS method that has the best outcomes has always been the main concern of physicians. The current study aimed to compare nutritional, anthropometric, and psychological complications of individuals undergoing various MBS Techniques.
View Article and Find Full Text PDFSurg Obes Relat Dis
January 2025
Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York; Division of Health Services Policy and Practice, Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York.
Background: Earlier evidence indicated that metabolic and bariatric surgery (MBS) may adversely affect neonatal outcomes among patients conceiving soon after MBS, but recent studies demonstrated conflicting results, especially for new surgical techniques.
Objectives: The aim of this study was to assess the effects of MBS types and surgery to birth interval on maternal, birth, and nonbirth outcomes in women with severe obesity.
Setting: New York State's all-payer hospital discharge database (2008-2019).
Background: Transumbilical single-port sleeve gastrectomy (SPSG) is a minimally invasive bariatric surgery that offers cosmetic benefits. However, the procedure's feasibility in patients with higher BMI or taller stature remains debated. This study evaluates the outcomes of SPSG based on patient height and BMI.
View Article and Find Full Text PDFCurr Obes Rep
January 2025
South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.
Background: One Anastomosis Gastric Bypass (OAGB) is a modification of Mason's loop bypass procedure, which has become a well-established procedure in the field of Bariatric and Metabolic surgery (BMS). However, the optimal length of Biliopancreatic Limb (BPL) in OAGB remains an ongoing debate.
Objective: This review aims to analyse the current trends and evidence regarding different BPL lengths in OAGB and their impact on outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.